<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="3067">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 08, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04350450</url>
  </required_header>
  <id_info>
    <org_study_id>2020-11445</org_study_id>
    <nct_id>NCT04350450</nct_id>
  </id_info>
  <brief_title>Hydroxychloroquine Treatment of Healthcare Workers With COVID19 Illness at Montefiore</brief_title>
  <official_title>Hydroxychloroquine Treatment of Healthcare Workers With COVID19 Illness at Montefiore: a Review of Process Feasibility, Safety, and Clinical Outcomes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Montefiore Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Montefiore Medical Center</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Given the high prevalence of COVID19 illness (both SARS-CoV-2 RT-PCR confirmed and highly&#xD;
      suspect cases) among healthcare workers (HCW) within the Montefiore Health System (MHS),&#xD;
      hydroxychloroquine (HCQ) will be prescribed to healthcare workers who are at the highest risk&#xD;
      for severe COVID19 illness.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    PI withdrew the submission to the IRB&#xD;
  </why_stopped>
  <start_date type="Anticipated">April 2020</start_date>
  <completion_date type="Anticipated">August 2020</completion_date>
  <primary_completion_date type="Anticipated">August 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time to resolution of symptoms</measure>
    <time_frame>up to 4 weeks</time_frame>
    <description>Time that it takes for symptoms to be resolved in those who were treated vs untreated</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of days from onset of illness to symptom resolution</measure>
    <time_frame>up to 4 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of days to return to work</measure>
    <time_frame>up to 4 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of hospital admission in treated and untreated healthcare workers</measure>
    <time_frame>up to 4 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse effect of HCQ during treatment</measure>
    <time_frame>up to 5 days</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>COVID</condition>
  <condition>Coronavirus</condition>
  <condition>COVID-19</condition>
  <arm_group>
    <arm_group_label>Treatment Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Eligible participants will be offered the standard Montefiore HCQ dosing regimen of 400mg every 12 hours x 24 hours, then 400mg daily for remaining 4 days and complete a survey study</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control Group</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Participants who opt not to receive the study drug will also be invited to participate in the survey study assessing COVID19 symptoms</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Hydroxychloroquine</intervention_name>
    <description>400 mg tablet</description>
    <arm_group_label>Treatment Group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Symptomatic with COVID illness (either RT-PCR test confirmed or highly suspect&#xD;
             clinical symptoms)&#xD;
&#xD;
          -  Call into office within the first 7 days of illness&#xD;
&#xD;
          -  Have any of the following high risk conditions:&#xD;
&#xD;
               -  Age &gt;60&#xD;
&#xD;
               -  HTN, CAD, or chronic heart disease&#xD;
&#xD;
               -  Diabetes&#xD;
&#xD;
               -  Chronic kidney disease&#xD;
&#xD;
               -  Chronic lung disease&#xD;
&#xD;
               -  Active or recent chemotherapy for malignancy&#xD;
&#xD;
               -  Organ transplant&#xD;
&#xD;
               -  Taking Immune-suppressing medications&#xD;
&#xD;
               -  HIV with CD4 &lt;200 cells/mm3&#xD;
&#xD;
          -  Experiencing at least one of the following high risk symptoms:&#xD;
&#xD;
               -  Severe cough&#xD;
&#xD;
               -  Fever 100.0F or greater&#xD;
&#xD;
               -  Diarrhea&#xD;
&#xD;
               -  Shortness of Breath&#xD;
&#xD;
               -  Hypoxia&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        â€¢ HCW not meeting high-risk criteria or those with a contraindication to HCQ will not be&#xD;
        offered HCQ&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>99 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Priya Nori, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Montefiore Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Montefiore Medical Center</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <zip>10467</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>April 14, 2020</study_first_submitted>
  <study_first_submitted_qc>April 14, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">April 17, 2020</study_first_posted>
  <last_update_submitted>May 22, 2020</last_update_submitted>
  <last_update_submitted_qc>May 22, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 27, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Montefiore Medical Center</investigator_affiliation>
    <investigator_full_name>Priya Nori</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronavirus Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hydroxychloroquine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

